Search results
Showing 811 to 825 of 2026 results for nice guidelines
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.
NICE's partners
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .
Biographies for all current members of the diagnostics advisory committee.
Our resource planner tool to help you plan for and implement NICE guidance.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)
Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.
View recommendations for HTG560Show all sections
Abaloparatide for treating osteoporosis after menopause (TA991)
Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
delivers a cancer-killing medicine directly to them. News 04 June 2026 NICE issues new guidance on 'artificial pancreas' technology for...